Robert J. Bitterman, chairman, president and chief executive officer of Phio Pharmaceuticals Corp. (PHIO), received 400,000 shares through an award or grant on September 28, 2026, according to an SEC Form 4 report published September 29.

The supplied SEC summary identifies the transaction as an award or grant. It does not describe an open-market purchase or a sale. The report also indicates that the transaction was not associated with a Rule 10b5-1 trading plan.

What the SEC report says

The September 29 filing report names Bitterman as the reporting insider and Phio Pharmaceuticals as the company involved. His listed positions combine leadership of the board with the roles of president and CEO.

The reported amount is 400,000 shares. That figure represents a share count, not a dollar valuation. The transaction date, September 28, is distinct from the September 29 publication date attached to the SEC report, which carries a timestamp of 20:01:05 UTC.

These details establish the recipient, company, transaction classification, amount and reported timing. The supplied summary does not provide a price per share, total award value or Bitterman's ownership balance after the transaction.

What the disclosure cannot establish

The available information does not specify vesting conditions, performance requirements or other terms of the award. It also does not explain why the shares were granted. Without those details, the report cannot establish when any conditions attached to the award would be satisfied.

Analysis: An equity award adds information about an executive's reported share transactions, but its classification matters when interpreting it. This disclosure alone does not establish that Bitterman committed personal funds to buy shares, nor does it demonstrate a view about PHIO's future market performance.

What to watch

The underlying filing and any related disclosures would be the places to check for award terms, valuation details and resulting ownership. Those details are absent from the supplied summary and would be needed for a fuller assessment.